Adversity is less terrifying than hope: uniQure N.V. (QURE)

uniQure N.V. (NASDAQ: QURE) stock jumped 7.15% on Friday to $6.89 against a previous-day closing price of $6.43. With 0.65 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.28 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.96 whereas the lowest price it dropped to was $6.38. The 52-week range on QURE shows that it touched its highest point at $28.25 and its lowest point at $5.49 during that stretch. It currently has a 1-year price target of $32.42. Beta for the stock currently stands at 1.00.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of QURE was up-trending over the past week, with a rise of 13.70%, but this was up by 11.49% over a month. Three-month performance dropped to -22.50% while six-month performance fell -67.61%. The stock lost -68.22% in the past year, while it has lost -69.61% so far this year. A look at the trailing 12-month EPS for QURE yields -4.80 with Next year EPS estimates of -3.97. For the next quarter, that number is -1.35. This implies an EPS growth rate of -127.23% for this year and 35.60% for next year.

Float and Shares Shorts:

At present, 46.97 million QURE shares are outstanding with a float of 42.51 million shares on hand for trading. On Oct 30, 2023, short shares totaled 3.15 million, which was 6.58% higher than short shares on Sep 28, 2023. In addition to Mr. Matthew Craig Kapusta as the firm’s CEO & Executive Director, Mr. Christian Klemt serves as its CFO, Principal Financial Officer & GM of Amsterdam Site.

Institutional Ownership:

Other institutions hold 45.42% of QURE, in contrast to 28.92% held by mutual funds. Shares owned by individuals account for 12.70%. As the largest shareholder in QURE with 7.22% of the stake, SSgA Funds Management, Inc. holds 3,450,282 shares worth 3,450,282. A second-largest stockholder of QURE, Nantahala Capital Management LLC, holds 3,023,799 shares, controlling over 6.33% of the firm’s shares. Morgan Stanley & Co. LLC is the third largest shareholder in QURE, holding 2,631,591 shares or 5.51% stake. With a 7.09% stake in QURE, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 3,386,992 shares are owned by the mutual fund manager. The Worldwide Healthcare Trust Plc, which owns about 2.82% of QURE stock, is the second-largest Mutual Fund holder. It holds 1,347,900 shares valued at 7.68 million. Government Pension Fund – Global holds 1.62% of the stake in QURE, owning 773,494 shares worth 4.41 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for QURE since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With QURE analysts setting a high price target of $63.00 and a low target of $14.00, the average target price over the next 12 months is $32.42. Based on these targets, QURE could surge 814.37% to reach the target high and rise by 103.19% to reach the target low. Reaching the average price target will result in a growth of 370.54% from current levels.

Summary of Insider Activity:

Insiders traded QURE stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 5,841 shares were sold. The number of buy transactions has increased to 27 while that of sell transactions has risen to 45 over the past year. The total number of shares bought during that period was 443,125 while 144,813 shares were sold.